Piper Sandler Downgrades Fulcrum Therapeutics to Underweight From Overweight, Adjusts PT to $3 From $23

Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts PT to $3 From $25

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Jefferies Downgrades Abivax SA to Hold From Buy, Adjusts PT to $90 From $160